Patrick Fabbio
Chief Financial OfficerMr. Patrick Fabbio, also known as Pat, M.B.A., served as Chief Financial Officer at Rafael Holdings, Inc. since September 2021 until January 27, 2023 and served as its President since November 21, 2021 until January 27, 2023. He serves as Chief financial Officer at Protara Therapeutics, Inc. since January 30, 2023. He served as the Chief Financial Officer of WindMIL Therapeutics, Inc. since March 2020 until September 2021. Mr. Fabbio had been Consultant of Progenics Pharmaceuticals, Inc. from March 27, 2020 to May 15, 2020. Mr. Fabbio served as Executive Vice President of Progenics Pharmaceuticals, Inc. from March 2019 to March 27, 2020, Chief Financial Officer from November 16, 2015 to March 27, 2020 and also served as its Senior Vice President from November 16, 2015 to March 2019. Mr. Fabbio has been an Independent Director of BeyondSpring Inc., since January 2, 2018. He has financial leadership experience with both public and private life science and pharmaceutical companies. Prior to joining Progenics in November 2015, he was Chief Financial Officer of electroCore LLC (also known as electroCore Medical, LLC), where he developed the corporate finance strategy supporting additional financing in preparation for FDA approval and launch. Mr. Fabbio served as the Chief Financial Officer of Ikano Therapeutics Inc. since May 2009. Prior to NPS, he served in senior financial positions including Vice President of Finance, Innovation and Growth of Catalent Pharma Solutions Inc. Mr. Fabbio served as Senior Director of US Life Cycle Management & Base Business at sanofi-aventis, where he served senior corporate finance, transactional and operational positions. He served as Vice President of Finance at NPS Pharmaceuticals, Inc. He served as Vice President of Commercial Operations at Unipath Diagnostics, a division of Unilever and as Corporate Controller at Biomatrix. He began his career at Coopers & Lybrand. He is a Certified Public Accountant. Mr. Fabbio graduated BBA in Accounting from Pace University and earned an MBA in Finance from the Stern School of Business at New York University.
Positions
- Company NameProtara Therapeutics, Inc.Stock CodeTARAPositionChief Financial OfficerColleagues
- JSJesse SheffermanCo-founder, CEO, President & Director
- LMLuke M. BesharIndependent Chairman of the Board
- JZJacqueline ZummoCo-Founder, Chief R&D Officer
- HFHannah FryVP, Principal Accounting Officer & Controller
- JOJustine O’MalleySenior Vice President of Investor Relations & Corporate Affairs
- GPGregory P. SargenIndependent Director
- CSCynthia SmithIndependent Director
- RJRoger J. GarceauIndependent Director
- Company NameBeyondSpring Inc.Stock CodeBYSIPositionIndependent DirectorColleagues
- LHLan HuangCo-Founder & Chair of the Board
- JLJune LuChief Scientific Officer
- MQMin QiuChief Executive Officer
- LNLi NaChief Financial Officer
- SKStephen KilmerHead of Investor Relations
- JMJiangwen MajetiIndependent Vice Chairman
- MKMatthew KirkbyIndependent Director
- PFPatrick FabbioIndependent Director
- DWDouglas W. BlayneyMember of Scientific Advisors & Principal Investigators Board
